OncoMatch/Clinical Trials/NCT06151262
A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer
Is NCT06151262 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Trilaciclib+mFOLFIRINOX for pancreatic cancer.
Treatment: Trilaciclib+mFOLFIRINOX — To observe the incidence of chemotherapy-induced myelosuppression and the safety of Trilaciclib combined with mFOLFIRINOX in patients with advanced pancreatic cancer receiving first-line treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic antineoplastic therapy
Had received systemic antineoplastic therapy
Lab requirements
Blood counts
Neutrophil count ≥1.5×10^9/L; Hemoglobin ≥10g/dL; Platelet count ≥100×10^9/L
Kidney function
creatinine clearance(CCr)≥60ml/min
Liver function
Total bilirubin(TBIL)≤1.5×ULN; ALT and AST≤1.5×ULN
Major organ functions within 7 days prior to treatment shall meet the following criteria: a. Neutrophil count ≥1.5×10^9 /L； b. Hemoglobin ≥10g/dL； c. Platelet count ≥100×10^9 /L Biochemical examination shall meet the following standards: a、Total bilirubin(TBIL)≤1.5times the upper limit of normal value(ULN); b、ALT and AST≤1.5×ULN ; c、creatinine clearance(CCr)≥60ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06151262 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages